ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for USA.
This biologic product, the first biologic in ESTEVE's portfolio, is used for the long-term treatment of growth failure in patients aged 2 to 18 years due to a condition known as 'severe primary insulin-like-growth-factor-1 deficiency' (SPIGFD). Patients with this condition have low levels of the hormone insulin-like growth factor-1 or IGF-1, which is required for normal growth¹.
"As a rare disorder, patients suffering SPIGFD, often face difficulties associated with receiving a late correct diagnosis, with consequent delayed treatment initiation with limited access to appropriate therapy. This has a considerable impact on the physical health and quality of life of these patients². The disease awareness and the multidisciplinary approach are critical to improve those people's lives. This standard of care medicine is perfectly aligned with our strategy, focused on highly specialized treatments for high unmet medical and patient needs", confirms José María Giménez Arnau, Chief Scientific & Medical Officer of ESTEVE.
Increlex® was designated an 'orphan medicine' (a medicine used in rare diseases) in 2006¹. It is approved by the U.S. Food and Drug Administration (FDA)³ and European Medicines Agency (EMA)¹ and authorized in 40 territories.

References
1. Increlex | European Medicines Agency (EMA)
2. Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective - PubMed
3. Drug Approval Package: Increlex (Mecasermin [rDNA origin]) NDA #021839